Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Vitamin D analogs and bone: preclinical and clinical studies with eldecalcitol.

Matsumoto T, Takano T, Saito H, Takahashi F.

Bonekey Rep. 2014 Mar 5;3:513. doi: 10.1038/bonekey.2014.8. eCollection 2014. Review.

2.

Eldecalcitol and calcitriol stimulates 'bone minimodeling,' focal bone formation without prior bone resorption, in rat trabecular bone.

Saito H, Takeda S, Amizuka N.

J Steroid Biochem Mol Biol. 2013 Jul;136:178-82. doi: 10.1016/j.jsbmb.2012.10.004. Epub 2012 Oct 13. Review.

PMID:
23069645
3.

Eldecalcitol for the treatment of osteoporosis.

Matsumoto T, Endo I.

Drugs Today (Barc). 2012 Mar;48(3):189-96. doi: 10.1358/dot.2012.48.3.1745223. Review.

PMID:
22462038
4.

A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures--a randomized, active comparator, double-blind study.

Matsumoto T, Ito M, Hayashi Y, Hirota T, Tanigawara Y, Sone T, Fukunaga M, Shiraki M, Nakamura T.

Bone. 2011 Oct;49(4):605-12. doi: 10.1016/j.bone.2011.07.011. Epub 2011 Jul 19.

5.

Comparison of the effects of eldecalcitol and alfacalcidol on bone and calcium metabolism.

Matsumoto T, Takano T, Yamakido S, Takahashi F, Tsuji N.

J Steroid Biochem Mol Biol. 2010 Jul;121(1-2):261-4. doi: 10.1016/j.jsbmb.2010.03.035. Epub 2010 Mar 16.

PMID:
20298784
6.

Eldecalcitol for the treatment of osteoporosis.

Noguchi Y, Kawate H, Nomura M, Takayanagi R.

Clin Interv Aging. 2013;8:1313-21. doi: 10.2147/CIA.S49825. Epub 2013 Sep 27. Review.

7.

Vitamin D3 analogs for the treatment of osteoporosis.

Hagino H.

Can J Physiol Pharmacol. 2015 May;93(5):327-32. doi: 10.1139/cjpp-2014-0419. Epub 2015 Jan 28. Review.

PMID:
25853632
8.

[Frontiers in vitamin D; basic research and clinical application. Eldecalcitol: the effect on bones and calcium metabolism].

Endo I, Matsumoto T.

Clin Calcium. 2011 Nov;21(11):103-10. doi: CliCa111116871694. Review. Japanese.

PMID:
22040826
9.

Osteoporosis treatment by a new active vitamin D3 compound, eldecalcitol, in Japan.

Matsumoto T.

Curr Osteoporos Rep. 2012 Dec;10(4):248-50. doi: 10.1007/s11914-012-0116-1.

PMID:
22918710
10.

Eldecalcitol: newly developed active vitamin D(3) analog for the treatment of osteoporosis.

Hagino H.

Expert Opin Pharmacother. 2013 Apr;14(6):817-25. doi: 10.1517/14656566.2013.778825. Epub 2013 Mar 11. Review.

PMID:
23477453
11.

Vitamin D endocrine system and osteoclasts.

Takahashi N, Udagawa N, Suda T.

Bonekey Rep. 2014 Feb 5;3:495. doi: 10.1038/bonekey.2013.229. eCollection 2014. Erratum in: Bonekey Rep. 2014;3:522. Udagawa, Naoyuki [corrected to Udagawa, Nobuyuki].

12.
13.

Relationship between the effect of eldecalcitol and serum 25(OH)D level.

Takano T, Kondo S, Saito H, Matsumoto T; Eldecalcitol Study Group.

J Steroid Biochem Mol Biol. 2014 Oct;144 Pt A:124-7. doi: 10.1016/j.jsbmb.2013.11.005. Epub 2013 Nov 15.

14.

Eldecalcitol: a review of its use in the treatment of osteoporosis.

Sanford M, McCormack PL.

Drugs. 2011 Sep 10;71(13):1755-70. doi: 10.2165/11206790-000000000-00000. Review. Erratum in: Drugs. 2011 Dec 24;71(18):2390.

PMID:
21902297
15.

Spotlight on eldecalcitol in osteoporosis.

Sanford M, McCormack PL.

Drugs Aging. 2012 Jan 1;29(1):69-71. doi: 10.2165/11207790-000000000-00000.

PMID:
22191725
16.

Long-term treatment with eldecalcitol (1α, 25-dihydroxy-2β- (3-hydroxypropyloxy) vitamin D3) suppresses bone turnover and leads to prevention of bone loss and bone fragility in ovariectomized rats.

Takeda S, Smith SY, Tamura T, Saito H, Takahashi F, Samadfam R, Haile S, Doyle N, Endo K.

Calcif Tissue Int. 2015 Jan;96(1):45-55. doi: 10.1007/s00223-014-9937-5. Epub 2014 Dec 4.

PMID:
25467010
17.

[Active vitamin D3 analog].

Takata S.

Nihon Rinsho. 2015 Oct;73(10):1701-5. Japanese.

PMID:
26529933
18.

Eldecalcitol is more effective for the prevention of osteoporotic fractures than alfacalcidol.

Nakamura T, Takano T, Fukunaga M, Shiraki M, Matsumoto T.

J Bone Miner Metab. 2013 Jul;31(4):417-22. doi: 10.1007/s00774-012-0418-5. Epub 2013 Apr 11.

19.

Multifunctional and potent roles of the 3-hydroxypropoxy group provide eldecalcitol's benefit in osteoporosis treatment.

Ono Y.

J Steroid Biochem Mol Biol. 2014 Jan;139:88-97. doi: 10.1016/j.jsbmb.2013.10.007. Epub 2013 Oct 16. Review.

PMID:
24139874
20.

Eldecalcitol reduces the risk of severe vertebral fractures and improves the health-related quality of life in patients with osteoporosis.

Hagino H, Takano T, Fukunaga M, Shiraki M, Nakamura T, Matsumoto T.

J Bone Miner Metab. 2013 Mar;31(2):183-9. doi: 10.1007/s00774-012-0397-6. Epub 2012 Nov 6.

Supplemental Content

Support Center